214 related articles for article (PubMed ID: 19185918)
1. Level of DNA topoisomerase IIalpha mRNA predicts the treatment response of relapsed acute leukemic patients.
Wang YH; Takanashi M; Tsuji K; Tanaka N; Shiseki M; Mori N; Motoji T
Leuk Res; 2009 Jul; 33(7):902-7. PubMed ID: 19185918
[TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIalpha mRNA and protein expression vs. in vitro drug resistance and clinical outcome in acute leukaemia.
Uggla B; Tina E; Nahi H; Paul C; Höglund M; Sirsjö A; Tidefelt U
Int J Oncol; 2007 Jul; 31(1):153-60. PubMed ID: 17549416
[TBL] [Abstract][Full Text] [Related]
3. DNA topoisomerase IIalpha and -beta expression in human ovarian cancer.
Withoff S; van der Zee AG; de Jong S; Hollema H; Smit EF; Mulder NH; de Vries EG
Br J Cancer; 1999 Feb; 79(5-6):748-53. PubMed ID: 10070864
[TBL] [Abstract][Full Text] [Related]
4. Quantitative analysis of topoisomerase IIalpha to rapidly evaluate cell proliferation in brain tumors.
Oda M; Arakawa Y; Kano H; Kawabata Y; Katsuki T; Shirahata M; Ono M; Yamana N; Hashimoto N; Takahashi JA
Biochem Biophys Res Commun; 2005 Jun; 331(4):971-6. PubMed ID: 15882973
[TBL] [Abstract][Full Text] [Related]
5. Adenovirus-mediated human topoisomerase IIalpha gene transfer increases the sensitivity of etoposide-resistant human breast cancer cells.
Zhou Z; Zwelling LA; Kawakami Y; An T; Kobayashi K; Herzog C; Kleinerman ES
Cancer Res; 1999 Sep; 59(18):4618-24. PubMed ID: 10493516
[TBL] [Abstract][Full Text] [Related]
6. Topotecan-induced topoisomerase IIalpha expression increases the sensitivity of the CML cell line K562 to subsequent etoposide plus mitoxantrone treatment.
Chen S; Gomez SP; McCarley D; Mainwaring MG
Cancer Chemother Pharmacol; 2002 May; 49(5):347-55. PubMed ID: 11976828
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of beta-catenin and topoisomerase IIalpha in de novo acute myeloid leukemia.
Chen CC; Gau JP; You JY; Lee KD; Yu YB; Lu CH; Lin JT; Lan C; Lo WH; Liu JM; Yang CF
Am J Hematol; 2009 Feb; 84(2):87-92. PubMed ID: 19127593
[TBL] [Abstract][Full Text] [Related]
8. Decreased topoisomerase IIα expression and altered histone and regulatory factors of topoisomerase IIα promoter in patients with chronic benzene poisoning.
Yu K; Shi YF; Yang KY; Zhuang Y; Zhu RH; Xu X; Cai G
Toxicol Lett; 2011 Jun; 203(2):111-7. PubMed ID: 21382456
[TBL] [Abstract][Full Text] [Related]
9. hTERT mRNA levels by real-time RT-PCR in acute myelogenous leukemia.
Huh HJ; Huh JW; Yoo ES; Seong CM; Lee M; Hong KS; Chung WS
Am J Hematol; 2005 Aug; 79(4):267-73. PubMed ID: 16044449
[TBL] [Abstract][Full Text] [Related]
10. PRAME mRNA levels in cases with acute leukemia: clinical importance and future prospects.
Paydas S; Tanriverdi K; Yavuz S; Disel U; Baslamisli F; Burgut R
Am J Hematol; 2005 Aug; 79(4):257-61. PubMed ID: 16044453
[TBL] [Abstract][Full Text] [Related]
11. E1A specifically enhances sensitivity to topoisomerase IIalpha targeting anticancer drug by up-regulating the promoter activity.
Zhou Z; Guan H; Kleinerman ES
Mol Cancer Res; 2005 May; 3(5):271-5. PubMed ID: 15886298
[TBL] [Abstract][Full Text] [Related]
12. Amplification and overexpression of topoisomerase IIalpha predict response to anthracycline-based therapy in locally advanced breast cancer.
Coon JS; Marcus E; Gupta-Burt S; Seelig S; Jacobson K; Chen S; Renta V; Fronda G; Preisler HD
Clin Cancer Res; 2002 Apr; 8(4):1061-7. PubMed ID: 11948114
[TBL] [Abstract][Full Text] [Related]
13. The topoisomerase IIalpha expression correlates with survival in patients with advanced Hodgkin's lymphoma.
Provencio M; Corbacho C; Salas C; Millan I; Espana P; Bonilla F; Ramon Cajal S
Clin Cancer Res; 2003 Apr; 9(4):1406-11. PubMed ID: 12684412
[TBL] [Abstract][Full Text] [Related]
14. Topo IIα gene alterations correlated with survival in patients with diffuse large B-cell lymphoma.
Chen Z; Wang J; Zhang H; Liu D; Li Y; Xu Y; Tan D; Chen D; Zhao X; Wang G
Eur J Clin Invest; 2012 Mar; 42(3):310-20. PubMed ID: 21880040
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of apoptosis, proliferation, HER-2, and topoisomerase IIalpha for anthracycline chemotherapy in locally advanced breast cancer.
Arpino G; Ciocca DR; Weiss H; Allred DC; Daguerre P; Vargas-Roig L; Leuzzi M; Gago F; Elledge R; Mohsin SK
Breast Cancer Res Treat; 2005 Jul; 92(1):69-75. PubMed ID: 15980993
[TBL] [Abstract][Full Text] [Related]
16. DNA topoisomerase IIalpha in multiple myeloma: a marker of cell proliferation and not drug resistance.
Wilson CS; Medeiros LJ; Lai R; Butch AW; McCourty A; Kelly K; Brynes RK
Mod Pathol; 2001 Sep; 14(9):886-91. PubMed ID: 11557785
[TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II alpha gene expression in childhood acute lymphoblastic leukemia.
Klumper E; Giaccone G; Pieters R; Broekema G; van Ark-Otte J; van Wering ER; Kaspers GJ; Veerman AJ
Leukemia; 1995 Oct; 9(10):1653-60. PubMed ID: 7564505
[TBL] [Abstract][Full Text] [Related]
18. Topoisomerase IIalpha expression in pituitary adenomas and carcinomas: relationship to tumor behavior.
Vidal S; Kovacs K; Horvath E; Rotondo F; Kuroki T; Lloyd RV; Scheithauer BW
Mod Pathol; 2002 Nov; 15(11):1205-12. PubMed ID: 12429800
[TBL] [Abstract][Full Text] [Related]
19. Topoisomerase IIalpha expression in acute myeloid leukaemia cells that survive after exposure to daunorubicin or ara-C.
Tina E; Prenkert M; Höglund M; Paul C; Tidefelt U
Oncol Rep; 2009 Dec; 22(6):1527-31. PubMed ID: 19885609
[TBL] [Abstract][Full Text] [Related]
20. Immunohistochemical study on topoisomerase IIalpha, Ki-67 and cytokeratin-19 in oral lichen planus lesions.
Mattila R; Alanen K; Syrjänen S
Arch Dermatol Res; 2007 Jan; 298(8):381-8. PubMed ID: 17072627
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
